|
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial. |
|
|
Speakers' Bureau - SERVIER |
Research Funding - Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD; Roche; Sanofi; Servier/Pfizer |
Consulting or Advisory Role - AstraZeneca; MSD; Pierre Fabre; Sanofi |
Research Funding - AstraZeneca (Inst); BTG (Inst); MSD (Inst); Roche (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - SERVIER |
Travel, Accommodations, Expenses - Sanofi; Servier |
|
|
Honoraria - Agios; Amgen; Bayer; Bristol Myers Squibb; Incyte; LEO Pharma; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Sanofi; SERVIER; Viatris |
Consulting or Advisory Role - Agios; Amgen; Bayer; Bristol Myers Squib; Incyte; Merck Serono; MSD; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Pierre Fabre; Roche; Sanofi; Servier |
|
|
Honoraria - AMGEN; AstraZeneca; Pierre Fabre; Servier |
Consulting or Advisory Role - BIOVEN; MSD Oncology; Pierre Fabre; Servier; Sirtex Medical |
Travel, Accommodations, Expenses - MSD Oncology |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Ipsen; Roche; Sanofi; SERVIER |
|
|
Honoraria - Amgen; Ipsen; Pierre Fabre |
Consulting or Advisory Role - Advanced Accelerator Applications; Novartis; Novartis |
Travel, Accommodations, Expenses - Ipsen; Ipsen; Merck Serono; Novartis |
|
|
No Relationships to Disclose |